Claims for Patent: 8,637,475
✉ Email this page to a colleague
Summary for Patent: 8,637,475
Title: | Modified 2\' and 3\' nucleoside prodrugs for treating flaviviridae infections |
Abstract: | 2\' and/or 3\' prodrugs of 1\', 2\', 3\' or 4\'-branchednucleosides, and their pharmaceutically acceptable salts and derivatives are described. These prodrugs are useful in the prevention and treatment of Flaviviridae infections, including HCV infection, and other related conditions. Compounds and compositions of the prodrugs of the present invention are described. Methods and uses are also provided that include the administration of an effective amount of the prodrugs of the present invention, or their pharmaceutically acceptable salts or derivatives. These drugs may optionally be administered in combination or alteration with further anti-viral agents to prevent or treat Flaviviridae infections and other related conditions. |
Inventor(s): | Storer; Richard (Kent, GB), Gosselin; Gilles (Monpellier, FR), Sommadossi; Jean-Pierre (Cambridge, MA) |
Assignee: | Idenix Pharmaceuticals, Inc. (Cambridge, MA) University of Cagliari (Cagliari, IT) The Centre National de la Recherche Scientifique (Paris, FR) L\'Universite Montpelier II (Montpelier, FR) |
Application Number: | 13/168,895 |
Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for patent 8,637,475 |
Patent Claims: | 1. A compound of the Formula (XIII): ##STR00116## or a pharmaceutically acceptable salt thereof, wherein: R.sub.3 is selected from the group consisting of H; mono-, di-,
and tri-phosphate or a stabilized phosphate prodrug; acyl; a sulfonate ester; optionally substituted alkyl sulfonyl; optionally substituted arylsulfonyl; a lipid; an amino acid; a carbohydrate; a peptide; cholesterol; and a pharmaceutically
acceptable leaving group which when administered in vivo is capable of providing a compound wherein R.sub.3 is independently H, or mono-, di- or triphosphate; B is an optionally substituted 3-7 membered heterocyclic ring consisting of C, O and/or S
atoms; Base is selected from the group consisting of: ##STR00117## ##STR00118## wherein each R', R'', R''' and R'''' are independently selected from the group consisting of H, OH, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl,
substituted or unsubstituted alkynyl, cycloalkyl, Br-vinyl, --O-alkyl, O-alkenyl, O-alkynyl, O-aryl, O-aralkyl, --O-acyl, O-cycloalkyl, NH.sub.2, NH-alkyl, N-dialkyl, NH-acyl, N-aryl, N-aralkyl, NH-cycloalkyl, SH, S-alkyl, S-acyl, S-aryl, S-cycloalkyl,
S-aralkyl, F, Cl, Br, I, CN, COOH, CONH.sub.2, CO.sub.2-alkyl, CONH-alkyl, CON-dialkyl, OH, CF.sub.3, CH.sub.2OH, (CH.sub.2).sub.mOH, (CH.sub.2).sub.mNH.sub.2, (CH.sub.2).sub.mCOOH, (CH.sub.2).sub.mCN, (CH.sub.2).sub.mNO.sub.2 and
(CH.sub.2).sub.mCONH.sub.2; m is 0 or 1; W is C--R'' or N; T and V independently are CH or N; Q is CH, --CCl, --CBr, --CF, --CI, --CCN, --C--COOH, --C--CONH.sub.2, or N; Q.sub.1 and Q.sub.2 independently are N or C--R; R is H, alkyl, or acyl; and
Q.sub.3, Q.sub.4, Q.sub.5 and Q.sub.6 independently are N or CH.
2. A pharmaceutical composition comprising a compound of claim 1, and a pharmaceutically acceptable carrier. 3. A method for the treatment of a host infected with a hepatitis C virus, comprising administering an effective treatment amount of a compound as claimed in claim 1, or a pharmaceutically acceptable salt thereof. 4. The method of claim 3, wherein the compound or pharmaceutically acceptable salt thereof is administered in combination or alternation with a second anti-viral agent. 5. The method of claim 4, wherein the second anti-viral agent is selected from the group consisting of an interferon, a ribavirin, an interleukin, a NS3 protease inhibitor, a cysteine protease inhibitor, a phenan-threnequinone, a thiazolidine derivative, a thiazolidine, a benzanilide, a phenan-threnequinone, a helicase inhibitor, a polymerase inhibitor, a nucleotide analogue, a gliotoxin, a cerulenin, an antisense phosphorothioate oligodeoxynucleotide, an inhibitor of IRES-dependent translation, and a ribozyme. 6. The method of claim 5, wherein the second anti-viral agent is an interferon. 7. The method of claim 6, wherein the second anti-viral agent is selected from the group consisting of pegylated interferon alpha 2a, interferon alphacon-1, natural interferon, albuferon, interferon beta-1a, omega interferon, interferon alpha, interferon gamma, interferon tau, interferon delta and interferon gamma-1b. 8. The method of claim 3, wherein the compound or pharmaceutically acceptable salt thereof is in the form of a dosage unit. 9. The method of claim 8, wherein the dosage unit contains 50 to 1000 mg or 0.1 to 50 mg of the compound. 10. The method of claim 8, wherein the dosage unit is a tablet or capsule. 11. The method of claim 3, wherein the host is a human. |
Details for Patent 8,637,475
Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
---|---|---|---|---|---|---|---|
Biogen Inc. | AVONEX | interferon beta-1a | For Injection | 103628 | 05/17/1996 | ⤷ Try a Trial | 2022-06-28 |
Biogen Inc. | AVONEX | interferon beta-1a | Injection | 103628 | 05/28/2003 | ⤷ Try a Trial | 2022-06-28 |
Biogen Inc. | AVONEX | interferon beta-1a | Injection | 103628 | 02/27/2012 | ⤷ Try a Trial | 2022-06-28 |
Emd Serono, Inc. | REBIF | interferon beta-1a | Injection | 103780 | 03/07/2002 | ⤷ Try a Trial | 2022-06-28 |
Emd Serono, Inc. | REBIF | interferon beta-1a | Injection | 103780 | 12/17/2004 | ⤷ Try a Trial | 2022-06-28 |
Emd Serono, Inc. | REBIF | interferon beta-1a | Injection | 103780 | 12/21/2012 | ⤷ Try a Trial | 2022-06-28 |
Horizon Therapeutics Ireland Dac | ACTIMMUNE | interferon gamma-1b | Injection | 103836 | 02/25/1999 | ⤷ Try a Trial | 2022-06-28 |
>Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.